Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synthes and Kensey Nash sign ECM products agreement

This article was originally published in Clinica

Executive Summary

Swiss orthopaedic specialist Synthes has broadened its offering of biomaterial products after signing a distribution agreement for products based on Kensey Nash’s extracellular matrix (ECM) technology. Under the terms of the deal, Kensey Nash (Exton, Pennsylvania) will use its technology for processing porcine-derived ECM tissues to develop and manufacture products, which Synthes will then market and distribute for certain reconstructive surgical applications. According to Synthes, the ECM products can be quickly repopulated with cells from the host tissue due to rapid revascularisation characteristics. The biomaterial is to be used in a wide of soft tissue reinforcement procedures, such as abdominal repairs and head, neck and chest reconstructions. Financial terms of the partnership were not disclosed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044130

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel